Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.

Alimentary pharmacology & therapeutics - 1 Feb 2004

Wong V W-S, Chan H L-Y, Wong M L, Tam J S-L, Leung N W-Y

Abstract excerpt

BACKGROUND: The efficacy of lamivudine therapy in chronic hepatitis B is well established. However, drug-resistant YMDD mutants emerge with extended therapy. This may result in the resurgence of viral replication, the return of hepatitis and histological deterioration. AIM: To study the safety of stopping lamivudine when the drug is no longer effective. METHODS: In the 5-year Asian Lamivudine Study, 34 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B virus

Share to Lamivudine

Share to Mutation

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 14984379
DOI: 10.1111/j.1365-2036.2004.01845.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.PMID 14984379Read ↗

Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy.Semantic proximity Read ↗

High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study.Semantic proximity Read ↗

Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine.Semantic proximity Read ↗

Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.Semantic proximity Read ↗

Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naive patients: a pilot study.Semantic proximity Read ↗

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.Semantic proximity Read ↗

Prolonged persistence of lamivudine-resistant mutant and emergence of new lamivudine-resistant mutants two years after lamivudine withdrawal in HBsAg-positive chronic hepatitis patient: a case report.Semantic proximity Read ↗

Absence of pretreatment markers that predict the emergence of YMDD mutants during lamivudine treatment--the results of a prospective multi-center study.Semantic proximity Read ↗

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.Semantic proximity Read ↗

Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.Semantic proximity Read ↗

Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.Semantic proximity Read ↗

No benefit to continue lamivudine therapy after emergence of YMDD mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.